Lenalidomide Not-Refractory, Relapsed Refractory Multiple Myeloma (RRMM), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Phase 3, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd)
### Instruction:
Identify the study with the following condition. 
### Input:
Lenalidomide Not-Refractory, Relapsed Refractory Multiple Myeloma (RRMM), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Phase 3, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd) 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391